Wedbush Maintains Outperform on Alpine Immune Sciences, Raises Price Target to $35
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll has maintained an Outperform rating on Alpine Immune Sciences (NASDAQ:ALPN) and increased the price target from $26 to $35.
January 26, 2024 | 1:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Robert Driscoll maintains an Outperform rating on Alpine Immune Sciences and raises the price target from $26 to $35.
The increase in price target by a reputable analyst typically signals a strong conviction in the company's future performance and growth potential. This can lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100